Navigation Links
Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009
Date:9/17/2009

TROY, Mich., Sept. 17 /PRNewswire-FirstCall/ -- Somanetics Corporation (Nasdaq: SMTS) today reported net revenues of $12.5 million for the third quarter ended August 31, 2009, a one percent increase from $12.4 million in the same period of 2008. For the nine months ended August 31, 2009, net revenues increased five percent to $35.5 million from $33.8 million.

U.S. net revenues increased 10 percent to $10.4 million from $9.4 million in the third quarter of fiscal 2008. International net revenues were $2.1 million compared to $3.0 million. For the nine-month period, U.S. net revenues increased five percent to $28.4 million and international revenues increased five percent to $7.1 million.

Third quarter income before income taxes was $3.5 million compared to $4.7 million in the third quarter of 2008. Net income was $2.2 million, or $0.17 per diluted share, compared with $3.0 million, or $0.23 per diluted share.

For the nine months ended August 31, 2009, income before income taxes was $8.5 million, compared to $11.3 million a year ago. Net income was $5.3 million for the nine-month period, or $0.41 per diluted share, compared with $7.1 million, or $0.51 per diluted share in the same period of 2008.

Gross margin was 88 percent in the third quarter of fiscal 2009, compared to 86 percent in the fiscal 2008 third quarter, and was 87 percent for the nine-month period of 2009, the same as a year ago. Cash, marketable securities and long-term investments at August 31, 2009 totaled $77.7 million, with no borrowings.

"The global economic crisis continued to impact our business in the quarter with hospitals limiting capital spending and slowing adoption of new technology," said Bruce Barrett, Somanetics' president and chief executive officer. "Despite this backdrop, we continued to experience solid growth in our disposable sensor business."

International Sales

In the third quarter Somanetics announced the three-year extension of its long-standing exclusive distribution agreement with Covidien to distribute Somanetics' INVOS Cerebral/Somatic Oximeter products in Europe, the Middle East and Africa. The extension goes into effect on February 16, 2010, when the current agreement expires.

Sales and Marketing Activities

During the fourth quarter, Somanetics is scheduled to participate in 16 medical conferences, including the 2009 annual meeting of the American Society of Anesthesiologists and various regional and state cardiothoracic, perfusion, anesthesia, pediatric cardiac and critical care and neonatology association meetings.

Vital Sync Launch

The Vital Sync(TM) patient data management system was launched in the third quarter with installations at three beta test sites. The device integrates data from a broad array of hospital bedside devices, such as physiological monitors and ventilators, into a single bedside display for comparison, data management and storage. It has been designed to reduce the time and effort required to collect and organize critical patient data and view patient parameters on one time-synchronized graph. The device compiles data into one interactive display, to facilitate early detection of worsening patient conditions and provide data to refine treatment protocols.

Business Outlook

Somanetics is reiterating its previously announced guidance:

  • Fiscal 2009 net revenues between $50 million and $52 million.

  • Gross margin of approximately 86 percent and operating margin of approximately 20 percent.

  • Fiscal 2009 income before income taxes in the range of $11.2 million to $11.6 million.

Current estimates are based on market and economic conditions, including the assumption that the current economic downturn continues throughout fiscal 2009, and Somanetics' current plans to invest in several areas of its business. Such investments include clinical research, medical education, research and development projects, the continued development and market launch of the Vital Sync System and the addition of sales and clinical education personnel in the U.S. and international markets. Somanetics undertakes no obligation to update its estimates.

Somanetics to Host Conference Call

Somanetics will webcast its third quarter 2009 conference call at 10:00 a.m. (ET) today. To join the webcast, visit the Presentations & Webcasts page in the Investor Relations section of Somanetics' website at www.somanetics.com and click on the "Q3 2009 Somanetics Corporation Earnings Conference Call" link. The call also will be archived on the website.

About Somanetics

Somanetics Corporation (Nasdaq: SMTS) develops, manufactures and markets the INVOS((R)) Cerebral/Somatic Oximeter which noninvasively provides accurate, real-time blood oxygen measurements in patients greater than 2.5 kilograms, and trend monitoring of this parameter for individuals of any weight. The INVOS System is the only commercially-available cerebral/somatic oximeter proven to improve outcomes. Surgeons, anesthesiologists and other medical professionals can use data provided by the INVOS System, in conjunction with other available data, to identify oxygen imbalances in brain or other body tissue beneath the sensor and take necessary corrective action, potentially improving patient outcomes and reducing the costs of care. The INVOS System is the clinical reference standard in cerebral/somatic oximetry, with an 11-year market track record, more than 700 clinical references and implementation at more than 700 U.S. hospitals. Somanetics also develops, manufactures and markets the Vital Sync(TM) System, a device that integrates data from bedside devices into a single system for enhanced patient assessment and decision making, data management and data storage. Somanetics supports its customers through a direct U.S. sales force and clinical education team. Covidien markets INVOS System products in Europe, Canada, the Middle East and Africa and Edwards Lifesciences represents INVOS System products in Japan. For more information visit www.somanetics.com.

Safe-Harbor Statement

Except for historical information contained herein, the matters discussed in this news release, including financial guidance for fiscal year 2009, are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Actual results may differ significantly from results discussed in the forward-looking statements and may be affected by, among other things, economic conditions in general and in the healthcare market, including the recent global economic crisis, the demand for and market acceptance of our products in existing market segments and in new market segments we plan to pursue, our current dependence on the INVOS Cerebral/Somatic Oximeter and disposable sensors, our dependence on distributors for a substantial portion of our sales, our dependence on single-source suppliers, potential competition, the effective management of our growth, our ability to attract and retain key personnel, the potential for products liability claims, government regulation of our business, the challenges associated with developing new products and obtaining and maintaining regulatory approvals if necessary, research and development activities, the lengthy sales cycle for our products, sales employee turnover, changes in our actual or estimated future income, changes in accounting rules, enforceability and the costs of enforcement of our patents, potential infringements of others' patents, the effect of acquisitions and the other factors set forth from time to time in Somanetics' Securities and Exchange Commission filings, including Somanetics' 2008 Annual Report on Form 10-K filed on February 11, 2009 and its 2009 Quarterly Reports on Form 10-Q filed on March 31, 2009 and July 1, 2009.

(Tables to follow)

                                    BALANCE SHEETS

                                                 August 31,  November 30,
                                                    2009         2008
                                                    ----         ----
    ASSETS                                      (Unaudited)   (Audited)
    CURRENT ASSETS:
      Cash and cash equivalents                 $20,724,822  $37,166,141
      Marketable securities                      28,988,437   19,992,545
      Accounts receivable                         7,924,399    7,862,103
      Inventory                                   3,665,636    2,960,422
      Prepaid expenses                              363,007      597,460
      Accrued interest receivable                   184,409       16,667
      Deferred tax asset - current                  164,615      164,615
                                                    -------      -------
        Total current assets                     62,015,325   68,759,953
                                                 ----------   ----------
    PROPERTY AND EQUIPMENT (at cost):
      Demonstration and no capital cost sales
       equipment at customers                     4,322,125    3,919,296
      Machinery and equipment                     1,923,695    1,638,597
      Furniture and fixtures                        545,796      504,485
      Leasehold improvements                        197,450      197,450
                                                    -------      -------
        Total                                     6,989,066    6,259,828
      Less accumulated depreciation and
       amortization                              (4,021,496)  (3,418,697)
                                                 ----------   ----------
        Net property and equipment                2,967,570    2,841,131
                                                  ---------    ---------
    OTHER ASSETS:
      Long-term investments                      28,002,534   12,837,710
      Deferred tax asset - non-current            1,782,977    1,587,977
      Intangible assets, net                        237,081      246,318
      Goodwill                                    1,679,713    1,679,713
      Other                                          15,000       15,000
                                                     ------       ------
        Total other assets                       31,717,305   16,366,718
                                                 ----------   ----------
    TOTAL ASSETS                                $96,700,200  $87,967,802
                                                ===========  ===========

    LIABILITIES AND SHAREHOLDERS' EQUITY
    CURRENT LIABILITIES:
      Accounts payable                           $1,045,984   $1,271,058
      Accrued liabilities                         1,275,659    1,848,672
                                                  ---------    ---------
        Total current liabilities                 2,321,643    3,119,730
                                                  ---------    ---------
    COMMITMENTS AND CONTINGENCIES
    SHAREHOLDERS' EQUITY:
      Preferred shares; authorized, 1,000,000
       shares of $.01 par value; no shares
       issued or outstanding                            ---          ---
      Common shares; authorized, 20,000,000
       shares of $.01 par value; issued and
       outstanding, 12,088,962 shares at
       August 31, 2009, and 12,034,074 shares at
       November 30, 2008                            120,890      120,341
      Additional paid-in capital                 95,551,450   91,330,305
      Accumulated deficit                        (1,293,783)  (6,602,574)
                                                 ----------   ----------
        Total shareholders' equity               94,378,557   84,848,072
                                                 ----------   ----------
    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY  $96,700,200  $87,967,802
                                                ===========  ===========



                              STATEMENTS OF OPERATIONS
                                    (Unaudited)

                                 Three Months             Nine Months
                               Ended August 31,         Ended August 31,
                               ----------------         ----------------
                              2009         2008         2009        2008
                              ----         ----         ----        ----

    NET REVENUES          $12,513,135  $12,367,988  $35,500,049  $33,801,326
    COST OF SALES           1,542,901    1,717,858    4,727,137    4,413,939
                            ---------    ---------    ---------    ---------
     Gross Margin          10,970,234   10,650,130   30,772,912   29,387,387
                           ----------   ----------   ----------   ----------

    OPERATING EXPENSES:
     Research, development
      and engineering         476,184      332,236    1,395,926      894,574
     Selling, general and
      administrative        7,277,898    6,155,551   21,765,806   19,423,534
                            ---------    ---------   ----------   ----------
       Total operating
        expenses            7,754,082    6,487,787   23,161,732   20,318,108
                            ---------    ---------   ----------   ----------

    OPERATING INCOME        3,216,152    4,162,343    7,611,180    9,069,279
                            ---------    ---------    ---------    ---------

    OTHER INCOME:
     Interest income          312,271      562,178      912,493    2,197,280
                              -------      -------      -------    ---------
       Total other income     312,271      562,178      912,493    2,197,280
                              -------      -------      -------    ---------
    INCOME BEFORE INCOME
     TAXES                  3,528,423    4,724,521    8,523,673   11,266,559
                            ---------    ---------    ---------   ----------

    INCOME TAX EXPENSE     (1,299,377)  (1,678,067)  (3,214,882)  (4,139,424)
                           -----------  -----------  -----------  -----------

    NET INCOME             $2,229,046   $3,046,454   $5,308,791   $7,127,135
                           ----------   ----------   ----------   ----------

    NET INCOME PER COMMON
     SHARE - BASIC              $0.18        $0.25        $0.44        $0.55
                                -----        -----        -----        -----

    NET INCOME PER COMMON
     SHARE - DILUTED            $0.17        $0.23        $0.41        $0.51
                                -----        -----        -----        -----

    WEIGHTED AVERAGE
     SHARES OUTSTANDING
     - BASIC               12,088,962   12,079,089   12,061,559   12,889,638
                           ==========   ==========   ==========   ==========

    WEIGHTED AVERAGE
     SHARES OUTSTANDING
     - DILUTED             12,957,120   13,247,953   12,926,752   13,919,212
                           ==========   ==========   ==========   ==========


'/>"/>
SOURCE Somanetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien
2. Somanetics Corporation to Release Second Quarter 2009 Financial Results and Host Conference Call June 17, 2009
3. 25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates
4. Somanetics Announces New FDA 510(K) Clearance
5. Somanetics Reports Record Net Revenues and Income Before Income Taxes for Fourth Quarter and Fiscal 2008
6. Somanetics Corporation to Release Fourth Quarter and Fiscal 2008 Financial Results and Host Conference Call January 21, 2009
7. Somanetics Corporation to Present at Rodman & Renshaw Annual Global Investment Conference
8. Somanetics Announces Share Repurchase Program Increased By $15 Million
9. Somanetics Receives 510(k) Clearance From the FDA to Expand INVOS System Labeling
10. Somanetics Corporation to Present at Citigroup 2008 Healthcare Conference
11. Somanetics Announces Share Repurchase Program Increased by $15 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... , ... February 13, 2016 , ... Many individuals looking ... protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved into ... once more, but without the high-carb repercussions. IsoPasta has 30 grams of protein ...
(Date:2/13/2016)... ... 2016 , ... When an Au Pair comes all the way around the world ... for and they are often worried things won’t go well. More often than not, however, ... Au Pair of the Year winner’s all commented how their Au Pairs have become a ...
(Date:2/12/2016)... LA (PRWEB) , ... February 12, 2016 , ... The ... St. Landry and Evangeline Parishes. The purpose of these scholarships is to encourage ... encourage those individuals to seek employment within these two parishes. , “We have ...
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical ... in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the ... products in action, learn more about their chosen field and network with their colleagues. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a leader in cloud ... Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. ... their small and medium business (SMB) clients. , In recent years, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... SAN DIEGO and SEOUL, ... -- Silicon Biosys­tems Menarini and Macrogen, Inc. today ... clinical assays and innovative procedures for precision medicine ... to combine Silicon Biosystems, DEPArray™ digital-sorting technology with ... development of tests certified under the Clinical Laboratory ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
(Date:2/11/2016)... 2016 Stem cells are primitive cells found ... and the capacity to differentiate into mature cell types ... the first mouse embryonic stem cells were derived from ... that the first culturing of embryonic stem cells from ... produced until 2006 As a result of these discoveries, ...
Breaking Medicine Technology: